Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

• DOI: 10.1007/s00432-021-03818-w
• Publication Date: 2021-10-24T16:02:50Z
• Authors: Changlong He; Chengcheng Wei; Jun Wen; Shi Chen; Ling Chen; Yue Wu; Yifan Shen; Huili Bai; Yangli Zhang; Xueping Chen; Xiaosong Li
• Keywords: Adult; Male; 0301 basic medicine; China; Lung Neoplasms; DNA Mutational Analysis; Polymerase Chain Reaction; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Predictive Value of Tests; Carcinoma, Non-Small-Cell Lung; Humans; Genetic Testing; Aged; Aged, 80 and over; High-Throughput Nucleotide Sequencing; Middle Aged; 3. Good health; ErbB Receptors; Mutation; Female; Original Article – Cancer Research

By comparing the detection rate and type of targeted gene mutations in non-small cell lung cancer (NSCLC) between amplification refractory mutation system PCR (ARMS-PCR) next-generation sequencing (NGS), characteristics application advantages are explained, providing a basis for clinicians to effectively select corresponding methods.The cases genes were selected from First Affiliated Hospital Chongqing Medical University January 2016 October 2020. A sample 4467 was selected, they diagnosed with NSCLC by Pathological biopsy. Sample sources include surgical resection, bronchoscope biopsy, metastatic blood, sputum, cytology pleural effusion. Among them, 3665 detected ARMS-PCR technique, 802 NGS technology. The techniques EGFR (including exon 18, 19, 20, 21 so on) different samples compared, respectively.The total 47.6% while 42.4% which indicated that there significant difference two methods detecting (P < 0.001). In exons, is various. 19 evidently higher than detection, exons 20 statistically significantly lower detection. Moreover, multiple 16.3% much 2.7% different.It showed could direct drug use resistant patients. However, some rare loci be but importance directed meaning still unknown number too. Further research on new biomarkers technique needed early diagnosis, directing assessing therapy prognosis.